Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCDPHP Step Therapy Coverage Policy | OpenPayer
    Ask Trek AI about this page
    CurrentCapital District Physicians' Health Plan (CDPHP)Policy N/A

    Prescription Drug Step-Therapy Requirements

    Customize your policy alerts

    Sign up for all cdphp policy alerts

    Know when cdphp releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs step-therapy requirements for selected prescription products, including azilsartan/EDARBI products, fluticasone HFA inhalers, penicillamine or trientine capsules, and products pending CMS review.

    Policy Summary
    PayerCapital District Physicians' Health Plan (CDPHP)
    PolicyPrescription Drug Step-Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Next Review DateN/A
    Key ActionDocument a trial of Qvar inhaler before requesting coverage for fluticasone HFA unless the pulmonary cGvHD-BOS after alloHSCT exception applies.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Fluticasone HFA strengths affected
    365 daysDocumentation lookback period
    2Products requiring penicillamine tablets
    Pending CMS reviewARB and bempedoic acid criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Fluticasone HFA Initial Coverage

    Coverage of fluticasone propionate HFA aerosol inhaler is available when the applicable prerequisite or exception below is met.

    ALL of the following

    • ONE of the following

      • Trial of Qvar inhaler is required before coverage of fluticasone propionate 44 mcg/actuation HFA aerosol inhaler.

        If Qvar appears in the prescription profile within the last 365 days, additional documentation is not required.

      • The requested drug is for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome (cGvHD-BOS) after allogeneic hematopoietic stem cell transplantation (alloHSCT); the prerequisite Qvar trial is not required.

    Penicillamine or Trientine Capsule Coverage

    Coverage of the affected capsule products is available when the following prerequisite is met.

    ALL of the following

    • Trial of penicillamine tablets (generic for Depen) is required before coverage of penicillamine 250 mg capsules or trientine 500 mg capsules.

      If penicillamine tablets appear in the prescription profile within the last 365 days, additional documentation is not required.

    Provider Documentation and Action Requirements

    Step Therapy

    Document Qvar Trial for Fluticasone HFA

    Coverage of fluticasone propionate HFA aerosol inhaler requires documentation of a trial of Qvar inhaler, unless the request is for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome (cGvHD-BOS) after allogeneic hematopoietic stem cell transplantation (alloHSCT).

    • Affected product: fluticasone propionate 44 mcg/actuation HFA aerosol inhaler
    • Qvar trial is not required for cGvHD-BOS after alloHSCT.
    Documentation Required

    Fluticasone Documentation Lookback

    Additional documentation for the fluticasone HFA request is not required when the requested drug appears in the patient's prescription profile within the last 365 days.

    • Verify the prescription profile for fluticasone HFA use during the prior 365 days.
    Denial Risk

    Missing Qvar Trial May Result in Denial

    A fluticasone HFA request is at risk for denial when the required Qvar inhaler trial has not occurred and the cGvHD-BOS after alloHSCT exception does not apply.

    • Document the Qvar trial or establish the specified cGvHD-BOS after alloHSCT exception.
    • The prescription-profile lookback may remove the need for additional documentation, but does not replace the prerequisite trial unless the exception applies.

    Unsupported block type: step_therapy

    Documentation Required

    Penicillamine Documentation Lookback

    Additional documentation for penicillamine or trientine capsule therapy is not required when the required drug appears in the patient's prescription profile within the last 365 days.

    • Verify the prescription profile for the required drug during the prior 365 days.
    Denial Risk

    Missing Penicillamine Tablet Trial May Result in Denial

    A request for penicillamine or trientine capsules is at risk for denial when the required penicillamine tablet trial has not occurred.

    • Document prior penicillamine tablet therapy before submitting the capsule request.
    • The prescription-profile lookback may remove the need for additional documentation, but does not eliminate the tablet trial requirement.

    Policy Background

    This policy establishes step-therapy requirements for selected prescription products, including ARB products such as EDARBI, azilsartan medoxomil, and EDARBYCLOR; bempedoic acid products NEXLETOL and NEXLIZET; the three affected strengths of fluticasone propionate HFA inhalers; and penicillamine 250 mg or trientine 500 mg capsules. Criteria for the ARB and bempedoic acid products are pending CMS review. Fluticasone HFA generally requires a Qvar inhaler trial, except when requested for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation, while penicillamine or trientine capsules require a prior trial of penicillamine tablets.

    Clinical Definitions

    Definition
    TermcGvHD-BOS after alloHSCT
    DefinitionPulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
    Coverage relevanceWhen fluticasone HFA is requested for this condition, the prerequisite Qvar inhaler trial is not required.

    Initial Therapy Requirements

    Fluticasone HFA Step Therapy

    Initial coverage requires one of the following pathways:

    Fluticasone HFA prerequisite pathway

    • Qvar pathway: The patient has completed a trial of Qvar inhaler.
    • Transplant-related exception: The request is for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.

    Penicillamine or Trientine Step Therapy

    Initial coverage requires the following prerequisite therapy:

    Penicillamine or trientine capsule prerequisite

    • Required tablet trial: Trial of penicillamine tablets.

    Required Prerequisite Therapy

    StepPrerequisite therapyCovered productsException
    1Trial of Qvar inhalerFluticasone propionate HFA aerosol inhalersPrerequisite trial is not required when the drug is requested for pulmonary chronic graft-versus-host disease with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation (cGvHD-BOS after alloHSCT).
    StepPrerequisite therapyCovered productsAdditional documentation
    1Trial of penicillamine tablets, generic for DepenPenicillamine 250 mg capsules or trientine 500 mg capsulesIf penicillamine tablets appear in the prescription profile within the last 365 days, additional documentation is not required.
    Policy Summary
    PayerCapital District Physicians' Health Plan (CDPHP)
    PolicyPrescription Drug Step-Therapy Requirements
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 202745d
    Next Review DateN/A
    Key ActionDocument a trial of Qvar inhaler before requesting coverage for fluticasone HFA unless the pulmonary cGvHD-BOS after alloHSCT exception applies.
    SourceLink
    On This Page
    Coverage CriteriaProvider Documentation and Action RequirementsPolicy BackgroundClinical DefinitionsInitial Therapy RequirementsRequired Prerequisite Therapy